Sino Biopharma receives Chinese rights to two GSK respiratory drugs
Seeking Alpha ·
A unit of Sino Biopharmaceutical ( SBMFF ) has obtained commercialization rights to market two GSK ( GSK )-owned respiratory drugs in mainland China, the Hong Kong-listed drugmaker announced on Wednesday. As part of the transaction, Sino Biopharma ( SBHMY ) unit Chia Tai Tianqing
DYAX Investor Sentiment
Bullish (Long) 37% · Bearish (Short) 63%
422 participants
Related News
- Webster/Banco Santander deal spread widens on Trump Spain comments
- Lyft to acquire Serveo's Spanish bikeshare operations unit
- Waymo to roll out driverless vehicles in four new U.S. cities
- AEP to receive up to $3.26B DoE loan for Texas power grid upgrades
- JPMorgan Chase focuses on small company deals to juice M&A - report
- Nvidia Valuation Falls to Pre-AI Boom Low